Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis
This study is ongoing, but not recruiting participants.
Study NCT00004196 Information provided by National Cancer Institute (NCI)
First Received: January 21, 2000 Last Updated: May 30, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Melanoma (Skin)
Additional conditions recognized in this trial
Melanoma
Neoplasm Metastasis
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neoplastic Processes
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Pathologic Processes
Interventions listed in this trial
recombinant interferon alfa
polymerase chain reaction
adjuvant therapy
conventional surgery
lymphangiography
radionuclide imaging
sentinel lymph node biopsy
Additional drug interventions recognized in this trial
Adjuvants, Immunologic
Interferon Alfa-2a
Interferon Alfa-2b
Interferon Type I, Recombinant
Interferon-alpha
Interferons
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
University of Alabama at Birmingham
National Cancer Institute (NCI)
Back to top of Main Content
